Skip to content

Cipla shares edge higher on large exchange volumes, hopes of better sales

Cipla has been in the news recently after it signed a perpetual license agreement with Novartis Pharma AG to manufacture and market the Galvus range for the treatment of type 2 diabetes on April 10.

Read More

​ Cipla has been in the news recently after it signed a perpetual license agreement with Novartis Pharma AG to manufacture and market the Galvus range for the treatment of type 2 diabetes on April 10. Cipla has been in the news recently after it signed a perpetual license agreement with Novartis Pharma AG to manufacture and market the Galvus range for the treatment of type 2 diabetes on April 10.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish